The Series Of Seafood Recalls That Left Consumers Sick To Their Stomachs
Just eating raw oysters leaves room for many surprises. How meaty will they be? How briny? Will there be any residual sand inside? The luckiest consumers even find pearls. However, hundreds of unlucky oyster consumers were recently left with the worst of surprises: norovirus. From December 2024 to February 2025, several oyster farms across North America issued recalls due to norovirus contamination. These alerts came during the 2024 rise in food recalls during which seafood recalls alone affected millions.
The earliest recall included contaminated Fanny Bay, Sunseeker, and Cloudy Bar oysters harvested in British Columbia between late November and early December 2024. Taylor Shellfish Canada issued the recall, noting that the oysters were distributed to Alberta, British Columbia, and Ontario, Canada, as well as California.
Then, in the second week of December 2024, oysters from Pacific Northwest Shellfish and Union Bay Seafood were found to be contaminated with norovirus, so those two farms recalled Fanny Bay, Buckley Bay, and Royal Miyagi oysters harvested between December 1 and 9 in British Columbia, Canada -- they were shipped to at least 15 U.S. states. Ruco's Shellfish — a Washington-based oyster farm — also recalled oysters harvested from a section of the Hammersley Inlet between December 2 and 17.
Read more: Sandwich Chains That Serve The Best And Worst Tuna Salad, According To Online Reviews
The back-to-back oyster recalls did not just plague 2024. A Louisiana-based oyster farm and shellfish company issued a recall of oysters harvested after January 10, 2025, following a string of norovirus cases linked to a harvesting area around the Chandeleur Islands. The Louisiana Department of Health closed the harvesting area on February 4, and by February 25, most of the area had been reopened. However, the contaminated oysters still made it to 19 states, including Florida, Alabama, New York, Vermont, and Minnesota. There were at least 266 reported illnesses associated with the outbreak. All other Louisiana-harvested shellfish and seafood were deemed safe for consumption.
In all instances, government agencies instructed restaurants, retailers, and consumers alike not to purchase, sell, serve, or eat any of the oysters known to carry norovirus. The agencies also noted the importance of safe handling of the contaminated shellfish and proper sanitization of any surface that came in contact with the oysters to avoid cross contamination.
For more food and drink goodness, join The Takeout's newsletter. Get taste tests, food & drink news, deals from your favorite chains, recipes, cooking tips, and more!
Read the original article on The Takeout.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
4 hours ago
- Miami Herald
Lilly's experimental obesity drug shows promise in early study
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market. The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week. "The data look particularly strong, and should push the program back into investor conversations," Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to investors. Lilly has shared few details about eloralintide before now, as it's still in the early stages of testing. It's part of a class of drugs that mimic the hormone amylin, which slows digestion and makes people feel full longer. They're thought to be a gentler option for losing weight than currently available injections like Zepbound and Wegovy, which often have side effects like nausea and vomiting. The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting. Few details were provided, however, including information on risks and benefits based on dose. The promise of drugs that are easier to take than blockbusters like Lilly's Zepbound and its rival Wegovy, from Novo Nordisk A/S, has drawn increasing interest from companies hoping for a piece of pharma's hottest market. In March, Roche Holding AG entered into a $5.3 billion deal to co-develop and commercialize Zealand Pharma A/S' amylin drug, called petrelintide. It is seen as the one to beat in the amylin class, with early trials showing patients lost as much as 8.6% of their body weight in four months, with less nausea than Lilly and Novo's current therapies. AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market. New York-based startup Metsera Inc. is developing a related compound that may be taken less frequently than weekly shots like Zepbound and Wegovy. Lilly is already a leader in the obesity market, where Zepbound is capturing the majority of new prescriptions. The company has several promising next-generation products in the late stages of development, including a pill called orforglipron and an experimental shot that's thought to be even more effective for weight loss. The company is studying eloralintide alone and in combination with Zepbound - similar to the approach Novo is taking with its next-generation drug CagriSema, which combines an amylin component with semaglutide, the backbone of Wegovy and the diabetes drug Ozempic. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Yahoo
8 hours ago
- Yahoo
Insurance dispute costs Bridgeport man potentially life-saving treatment
BRIDGEPORT, (WBOY) — For the past two years, a Bridgeport, West Virginia man suffering from cancer has been searching for an operation that could improve his health, but after denials and disputes with his insurance provider, his family says that he may have missed his chance. A report from NBC News on Thursday night spoke about Eric Tennant, a Bridgeport resident who works at the West Virginia Office of Miners' Health Safety and Training and suffers from a rare cancer found in his bile ducts. He was diagnosed at stage 4 in 2023 and wasn't expected to survive a year, dropping below 100 pounds at one point. In fall 2024, following nearly two years of chemotherapy treatment, Tennant's wife, Rebecca, learned of a way to potentially aid his condition through a 'relatively new' procedure known as histotripsy, NBC News reported. The procedure would use ultrasound waves to target tumors in Tennant's liver and could potentially extend his life. His insurance declined to cover the $50,000 treatment. Tennant is insured under West Virginia's Public Employee Insurance Agency (PEIA), and despite receiving a recommendation for the procedure from his oncologist, PEIA cited the treatment as 'not medically necessary,' NBC News reported. West Virginia woman who traveled 6 hours for life-saving abortion calls for issue to be placed on voter ballot After learning of PEIA's denial, NBC News reported that the Tennant family attempted to appeal the agency four separate times, all to no avail. Along the way, they were faced with other roadblocks such as UMR, a subsidiary of United Healthcare that manages PEIA plans through a contract with West Virginia, as well as MES Peer Review Services, a Massachusetts-based company that upheld PEIA's decision in March, saying that histotripsy is 'unproven in this case and is not medically necessary.' NBC News interviewed the Tennants in April and noted that after it and KFF Health News reached out to PEIA with questions for its story, the agency changed its tune. PEIA officials told NBC News that the agency had 'consulted with medical experts to further evaluate the case' and that Tennant was now, seemingly out of nowhere, approved for a histotripsy. PEIA Director Brent Wolfingbarger told the outlet that the decision to approve Tennant 'reflects a rare and exceptional situation' and doesn't represent a change in PEIA's overall coverage policies. Despite the sudden approval, Rebecca Tennant told NBC News that it may be too late. She said that since Eric was evaluated in February, his health has declined significantly, resulting in him having to spend five days in the hospital in late May and early June due to lung and heart complications. As a result of his health declining, Rebecca told NBC News that Eric is no longer considered a viable candidate for a histotripsy. She said she's hopeful that he will be viable once again after his health improves, but blames PEIA for 'wasting months' of their time. 'Time is precious,' she said. 'They know he has stage 4 cancer, and it's almost like they don't care if he lives or dies.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Washington Post
9 hours ago
- Washington Post
US Senate seeks to add expanded compensation for nuclear radiation victims to tax bill
WASHINGTON — A program to compensate people exposed to radiation from past nuclear weapons testing and manufacturing could be restarted and expanded under a provision added by U.S. senators to the major tax and budget policy bill . The language added Thursday to the Senate version of the massive tax bill would overhaul the Radiation Exposure Compensation Act, which was originally enacted in 1990 and expired about a year ago. The law compensated people in about a dozen western states who developed serious illnesses from nuclear testing and manufacturing stemming from World War II-era efforts to develop the atomic bomb.
